| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Original Studies |
Developmental Endocrinology Branch, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20892
Address all correspondence and requests for reprints to: Dr. Penelope P. Feuillan, Developmental Endocrinology Branch, National Institute of Child Health and Human Development, National Institutes of Health, Building 10, Room 10N 262, Bethesda, Maryland 20892.
 |
Abstract |
|---|
 Top Abstract IntroductionSubjects and MethodsResultsDiscussionReferences |
|---|
|
Introduction |
|---|
|
TopAbstractIntroductionSubjects and MethodsResultsDiscussionReferences |
|---|
To assess the long term recovery of the pituitary-gonadal axis after discontinuation of GnRH analog therapy and to determine whether patients with hamartoma might be at increased risk for posttherapy reproductive disorders, we compared our findings in girls with precocious puberty and HH to those in girls with a diagnosis of IPP. To control for biases that could overestimate the incidence of adverse effects because one group was treated longer or began treatment at an earlier age, we selected a subgroup of IPP patients for whom age at the start of therapy (and hence the duration of therapy) was not different from that for the group of patients with HH. Patients were treated with GnRH analog for 3.1–10.3 yr (mean, 6.8 ± 1.9 yr) and were followed for 3–8 yr after treatment was stopped.
|
Subjects and Methods |
|---|
|
TopAbstractIntroductionSubjects and MethodsResultsDiscussionReferences |
|---|
The diagnosis of hamartoma was based on the finding of an isodense, pedunculated, nonenhancing mass in the area of the mammillary bodies using computed tomography and/or magnetic resonance imaging. Patients with nonhamartomatous intracranial masses (i.e. glioma or astrocytoma) or with gonadotropin-dependent puberty secondary to a gonadotropin-independent process (i.e. congenital adrenal hyperplasia, familial male precocious puberty, or McCune-Albright syndrome) were not included in this analysis.
Patients were treated with either deslorelin (D-Trp6,Pro9,NEt-LHRH; 4–8 µg/kg·day, sc; 46 patients) or histrelin (D-His[Bzl]6,Pro9,Net-LHRH; 10 µg/kg·day; 4 patients). Therapy was discontinued in most cases at the age when normal puberty would be expected (10–12 yr), but earlier (8–9 yr) in 2 patients (1 HH and 1 IPP) at the request of the family and patient. After discontinuation of treatment, girls were evaluated at 1- to 2-yr intervals at the Clinical Center at the NIH. Immunoreactive LH and FSH were measured (10) from 0–120 min after the iv administration of 100 µg GnRH at 0900 h. Serum estradiol (E2) was measured (11) at 0 min. Ovarian structure and dimensions were assessed using pelvic ultrasonography, and mean ovarian volume (MOV) was estimated using the formula: MOV = volume of left ovary + volume of right ovary/2. The frequency of menses was determined from monthly diaries maintained by the patient and her family. Because menses were frequently irregular, the in-hospital endocrine evaluations were performed without regard to the phase of the menstrual cycle.
The body mass index (BMI) was calculated from weight (kilograms)/height (meters)2, and the SD score was calculated from that of normal children using published standards (12).
For comparative purposes, we also measured LH and FSH (after administration of 100 µg GnRH), E2, MOV, and BMI in 14 normal, postmenarcheal girls, aged 13.0–15.5 yr (mean, 14.0 ± 0.9), with breast pubertal stages IV–V.
Statistical analyses
Hormonal and MOV findings are presented as the mean ± SD of all patients in each group evaluated at baseline (yr 0, before discontinuation of GnRH treatment) and at the 1, 2, 3, and 4–5 yr points thereafter. Data from 4 and 5 yr visits were evaluated as the mean of yr 4 and 5, when both time points were available. Endocrine data from two HH patients were not available after 2 yr; hence, they have been excluded from the hormonal analysis.
Comparisons of hormonal parameters (gonadotropin and estrogen levels
and ovarian volumes) and BMI were made using the t test. The
frequency of menstrual bleeding was classified for each year as
follows: 1, oligomenorrhea (menses at 60- to >150-day intervals); 2,
irregular (every 35–60 days); and 3, regular (every 25–35 days).
Comparisons between groups were made using the 
2
statistic. When a diary was unavailable for a posttherapy year, the
patient was excluded from that year’s analysis of menses.
|
Results |
|---|
|
TopAbstractIntroductionSubjects and MethodsResultsDiscussionReferences |
|---|
Before the start of GnRH analog therapy, the HH group had
significantly higher levels of peak GnRH-stimulated LH
(165.5 ± 129 vs. 97.5 ± 55.7 mIU/mL;
P < 0.02) and a higher peak LH/FSH ratio (5.4 ±
2.8 vs. 3.6 ± 2.4; P < 0.05) than the
IPP group. At discontinuation of treatment (0 yr), the mean peak LH and
FSH levels were also greater in HH than in IPP, but the groups did not
differ in this respect at any of the subsequent posttherapy time points
(Fig. 1
, A and B). By 1 yr posttherapy,
peak LH and FSH levels in both HH and IPP girls had entered the range
for normal pubertal stage IV–V girls (13). However, the mean peak LH
in both HH and IPP tended to be lower than that in normal girls at all
time points, whereas the peak FSH levels were comparable to normal, so
that the mean peak LH/FSH ratio for posttherapy yr 1–5 in both HH and
IPP was lower than that in normal girls (HH, 2.7 ± 0.3; IPP,
2.6 ± 0.1; normal, 5.2 ± 4.8; P <
0.05).
|
By 1 yr after stopping therapy and at all the subsequent time
points, E2 levels had risen from near or below
the assay detection limit in both HH and IPP and were not different
from normal (Fig. 1C
). Breast development was pubertal stage III in
78% of HH and 79% of IPP girls at 0 yr, and had progressed to stage V
in 53% of HH and 71% of IPP by 2 yr, in 81% of HH and 90% of IPP by
3 yr, and in all patients by 4–5 yr posttherapy.
The MOV was larger in HH than in IPP at discontinuation of therapy and
at 4–5 yr, but was not significantly different at the intermediate
time points. However, MOV tended to increase progressively in both
groups over the first 3 yr after treatment was stopped and was
significantly greater than that in the normal girls in HH at 3 yr and
those in both HH and IPP at 4–5 yr posttherapy (Fig. 1D). Small
(<1.0-cm) hypoechoic regions resembling follicles were observed in at
least 1 posttherapy ultrasound study in 10 HH and 16 IPP girls and in 2
or more studies in 7 HH and 13 IPP girls. Larger, well circumscribed,
more than 1.0-cm hypoechoic areas resembling cysts were observed at
least once in 4 HH and 16 IPP girls and recurred once in 2 HH and 4 IPP
girls. One IPP girl had recurrent, isolated, unilateral, 1.0- to 4.8-cm
hypoechoic, cyst-like areas in both right and left ovaries at each
yearly ultrasound study. Although the ultrasound appearance in this
patient was suggestive of polycystic ovarian syndrome (14), she
reported regular menses, she was not androgenized, and her LH levels
were normal at baseline (4.2–6.8 mIU/mL) and after GnRH treatment
(30.9–96.5 mIU/mL).
Two normal girls had multiple, bilateral hypoechoic areas, 0.2–1.0 cm in diameter. One asymptomatic normal girl had a large, unilateral hypoechoic area 5.0 x 8.0 cm in diameter, on a single ultrasound study.
Menses
The time interval between the discontinuation of GnRH analog and
the start of spontaneous menses varied widely in both groups and was
not significantly different in patients with HH (20.5 ± 16.3;
range, 0–60 months) and those with IPP (17.6 ± 11.0; range,
5–61 months). One HH patient began menstruating before discontinuation
of therapy despite a 2-fold increase in the dose of GnRH agonist
and apparently good compliance, and 1 other HH patient had persistent
primary amenorrhea, although she had withdrawal bleeding after a 10-day
challenge with medroxyprogesterone acetate at 4 yr posttherapy. There
were no significant differences between the groups in the mean CA
(13.4 ± 1.9 vs. 12.5 ± 0.7 yr) or BA (14.6
± 1.3 vs. 13.8 ± 1.0 yr) at the onset of spontaneous
menses. The number of girls reporting regular menses tended to increase
in both groups over the 4 yr of follow-up; however, in the subset of
girls who had begun spontaneous menses, a greater percentage of HH than
IPP girls reported oligomenorrhea during yr 2 [4 of 13 (30%)
vs. 0 of 24 (0%); P < 0.005] and yr 3 [3
of 13 (23%) vs. 1 of 31 (3%); P < 0.05]
posttherapy (Fig. 2). The MOV was not
significantly different in patients reporting oligomenorrhea
vs. those with regular menses (7. 8 ± 2.9
vs. 5.6 ± 2.5 mL).
|
).
|
)As expected, at the start of GnRH analog therapy, the mean BMI SD score of both HH (1.6 ± 1.2) and IPP (1.2 ± 1.3) girls was greater than that of normal girls of comparable age. At the end of therapy and at all the posttherapy time points, the mean BMI of both HH and IPP groups continued to exceed that of the normal girls, and marked obesity (BMI, 28.9–42.0, +2.0 to +5.2 SD score) was observed in five HH and in six IPP girls. Elective cosmetic breast reduction was performed in one HH and one IPP patient. The BMI and the incidence of obesity tended to be greater in HH than that in IPP, although this increase was not significantly different due to the wide variability among patients. Acanthosis nigricans (without clinically apparent insulin resistance) was observed in three HH girls with BMI values of +5.0, +3.0, and +0.9. Insulin resistance and hyperglycemia requiring treatment with oral agents and, eventually, insulin, was observed during and after GnRH analog therapy in one IPP patient who continued to menstruate regularly, but had mild hirsutism (BMI, +2.3) and reported a spontaneous abortion (see above).
|
Episodes of seizure, which were first noticed during the course of GnRH agonist therapy, were reported by 5 of 18 HH patients. Four patients were between 9 and 10 yr of age, and 1 was 11 yr. Anticonvulsants were used in all patients and were continued during and after discontinuation of GnRH analog therapy; however, 2 of these patients have been seizure free after discontinuation of anticonvulsant treatment. Diagnoses were reported as gelastic epilepsy in 1 girl and as complex partial seizure in 4 girls. No family has yet reported the onset of a seizure disorder after discontinuation of GnRH analog therapy. Emotional lability, depressive behavior, and mood swings without a diagnosis of seizure were reported in 2 additional HH patients after GnRH treatment was stopped. Whereas the mean hamartoma size was larger in HH girls reporting seizures than in those who were seizure free (maximum anterior-posterior diameter, 1.7 ± 1.2 vs. 0.9 ± 0.4 cm; P < 0.05) no girl had a documented change in the size of her hamartoma either during or after GnRH analog therapy.
A disorder diagnosed as benign nocturnal seizure of childhood developed during GnRH analog treatment in one IPP patient at 8 yr of age and was treated with anticonvulsants for 3 yr. This girl has been seizure free after discontinuation of GnRH analog.
|
Discussion |
|---|
|
TopAbstractIntroductionSubjects and MethodsResultsDiscussionReferences |
|---|
The pattern of relatively increased peak baseline LH and increased peak GnRH-stimulated LH/FSH ratio that we observed in the HH patients at initial presentation did not reemerge over the 5-yr posttreatment period. We did observe a significantly higher peak LH and increased MOV in the HH group at the end of treatment, and one such patient, with a MOV of 15.9 mL, who denied noncompliance, reported menarche and had a pubertal peak LH (28.8 mIU/mL) at 0 yr. Although these findings suggest resistance to GnRH analog or a higher pituitary gonadotropin reserve in HH, compliance may have been playing a major role despite the assertions of the patient and her family.
Although our findings confirm previous reports (5) that gonadotropin responses return to the normal range by 12 months after discontinuation of GnRH analog treatment, they also reveal that the peak GnRH-stimulated LH/FSH ratio after treatment tends to be low compared to that of normal girls. This may represent a blunted sensitivity to GnRH stimulation similar to that observed in normal women during the very early follicular phase of the menstrual cycle (16). However, it is not clear whether this is a consequence of prolonged suppression of the pituitary gonadotropes or represents the natural history of early maturation of the hypothalamic-pituitary-gonadal unit.
A previous study (7) indicated that ovarian volumes in girls who have stopped GnRH analog therapy return to pretreatment levels by 3 months and remain constant thereafter. However, these initial reports reflect findings in girls who were older (7.8 ± 1.1 yr) at the start of treatment and were treated for a shorter period of time (3.5 ± 0.9 yr) than those in the present groups. Our findings that ovarian volumes tend to increase progressively over the first 3 posttreatment years and were often larger than normal by 3 yr posttherapy suggest that recovery of the suppressed gonad of girls treated for longer periods of time may be a more gradual process, and that a complete picture of the effects of therapy may only emerge after several years have passed. The somewhat greater age and bone age at menarche, and the greater interval between discontinuation of therapy and menarche that we found in our patients compared to those reported by other observers (8) may also reflect the longer period of gonadal suppression and/or the early age when treatment was instituted. Nevertheless, it is reassuring that the mean age of menarche in our patients was comparable to that in normal girls and that seven patients have demonstrated fertility.
As has been noted by others (17), our patients’ ovaries were larger than those of normal postpubertal girls (18) and were comparable in size to those of cycling mature women (19, 20). Hypoechoic, cyst- or follicle-like areas were detected in most patients at one or more posttherapy time points and in three normal girls. Whereas irregular menses and obesity were common complaints in our patients, none of the girls with persistent hypoechoic regions in their ovaries had the elevated baseline or GnRH-stimulated gonadotropin levels that would suggest true polycystic ovarian syndrome. Although acanthosis nigricans was observed in three HH patients, two of whom had oligomenorrhea and moderate to marked obesity, none of the three had clinical diabetes mellitus. Conversely, the IPP girl with insulin-dependent diabetes and mild hirsutism was having regular menses. Although we did not measure androgen levels in our patients, elevated adrenal androgen responses have been observed by other groups (21) after GnRH analog treatment of IPP, and continuing follow-up will be needed to determine whether a fully developed polycystic ovary syndrome may eventually develop in any of these girls.
The timing of sexual maturation in normal females is linked to body fat content. Obese girls have earlier menarche than thin girls. Not surprisingly, as we and others (22) have reported, precocious puberty is also associated with increased body mass both at initial presentation and during GnRH analog treatment. Our current data show that this condition persists after discontinuation of therapy and progresses to frank obesity (BMI, >+2SD score) in many girls, more frequently in those with HH. Although it is tempting to implicate the hypothalamic abnormality in this trend toward obesity, there have been, to the best of our knowledge, only anecdotal reports (23) of an association between HH and extreme weight gain. Those who care for girls with precocious puberty may need to address this issue early in view of the morbidity that accompanies persistent obesity (24, 25).
HH has a known association with gelastic epilepsy (26, 27); however, only one HH patient carried this diagnosis, whereas four had partial complex seizure. In the HH patients as a group, seizures were associated with larger hamartomas, all seizures were first observed during GnRH analog treatment, and three of the six girls have been able to discontinue anticonvulsant therapy after stopping GnRH analog. Although it is not possible to determine from our data whether GnRH analog treatment delayed or, possibly, accelerated the onset of seizure in these patients, the lower incidence of seizure disorder in the IPP patients [1 of 32 girls; 3%, vs. 0.5% in normal children (28)] suggests that the preexisting neurological abnormality, rather than GnRH analog therapy, played the major roll.
Clinical trials using GnRH analogs to treat precocious puberty have not included untreated placebo control groups. Although the choice of an uncontrolled study design is understandable, it will be difficult to learn whether altered gonadotropin and gonadal androgen levels, changes in ovarian volume and structure, increased body weight, and neurological complications are a result of therapy or inevitable manifestations of the primary process. It is hoped that some or all of these issues will be resolved as these patients are followed throughout adulthood.
Received July 10, 1998.
Revised September 23, 1998.
Accepted October 5, 1998.
|
References |
|---|
|
TopAbstractIntroductionSubjects and MethodsResultsDiscussionReferences |
|---|
This article has been cited by other articles:
 |
|
 |
|
  A. M. Pasquino, I. Pucarelli, F. Accardo, V. Demiraj, M. Segni, and R. Di Nardo Long-Term Observation of 87 Girls with Idiopathic Central Precocious Puberty Treated with Gonadotropin-Releasing Hormone Analogs: Impact on Adult Height, Body Mass Index, Bone Mineral Content, and Reproductive Function J. Clin. Endocrinol. Metab., January 1, 2008; 93(1): 190 - 195. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Tanaka, H. Niimi, N. Matsuo, K. Fujieda, K. Tachibana, K. Ohyama, M. Satoh, and K. Kugu Results of Long-Term Follow-Up after Treatment of Central Precocious Puberty with Leuprorelin Acetate: Evaluation of Effectiveness of Treatment and Recovery of Gonadal Function. The TAP-144-SR Japanese Study Group on Central Precocious Puberty J. Clin. Endocrinol. Metab., March 1, 2005; 90(3): 1371 - 1376. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Jung, E. N. Probst, B. P. Hauffa, C.-J. Partsch, and O. Dammann Association of Morphological Characteristics with Precocious Puberty and/or Gelastic Seizures in Hypothalamic Hamartoma J. Clin. Endocrinol. Metab., October 1, 2003; 88(10): 4590 - 4595. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. M. Lee Is Treatment with a Luteinizing Hormone-Releasing Hormone Agonist Justified in Short Adolescents? N. Engl. J. Med., March 6, 2003; 348(10): 942 - 945. [Full Text] [PDF]
|
|
|
|
|
|
L. Lazar, R. Kauli, A. Pertzelan, and M. Phillip Gonadotropin-Suppressive Therapy in Girls with Early and Fast Puberty Affects the Pace of Puberty but Not Total Pubertal Growth or Final Height J. Clin. Endocrinol. Metab., May 1, 2002; 87(5): 2090 - 2094. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Arisaka, M. Negishi, M. Numata, M. Hoshi, S. Kanazawa, M. Oyama, A. Nitta, H. Suzumuara, T. Kuribayashi, and Y. Nakayama Precocious Puberty Resulting from Congenital Hypothalamic Hamartoma: Persistent Darkened Areolae After Birth as the Hallmark of Estrogen Excess Clinical Pediatrics, March 1, 2001; 40(3): 163 - 167. [PDF]
|
|
|
|
|
|
P. P. Feuillan, J. V. Jones, K. M. Barnes, K. Oerter-Klein, and G. B. Cutler Jr. Boys with Precocious Puberty Due to Hypothalamic Hamartoma: Reproductive Axis after Discontinuation of Gonadotropin-Releasing Hormone Analog Therapy J. Clin. Endocrinol. Metab., November 1, 2000; 85(11): 4036 - 4038. [Abstract] [Full Text]
|
|
|
|
|
|
Is Obesity an Outcome of Gonadotropin-Releasing Hormone Agonist Administration? Analysis of Growth and Body Composition in 110 Patients with Central Precocious Puberty J. Clin. Endocrinol. Metab., December 1, 1999; 84(12): 4480 - 4488. [Abstract] [Full Text]
|
|
|
|
|
|
Long-Term Outcome after Depot Gonadotropin-Releasing Hormone Agonist Treatment of Central Precocious Puberty: Final Height, Body Proportions, Body Composition, Bone Mineral Density, and Reproductive Function J. Clin. Endocrinol. Metab., December 1, 1999; 84(12): 4583 - 4590. [Abstract] [Full Text]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
,
P < 0.05 compared to yr 0; 
,
P < 0.001 compared to yr 0.
), oligomenorrhea
(
), irregular menses (
), and regular menses (
). Figures
below each column denote the number of patients. *,
P < 0.005, HH vs. IPP; **, P < 0.05,
HH vs. IPP.